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Renal proximal tubular epithelial cells, a target of infiltrating
T cells during renal allograft rejection, may be protected from
this injury by the cell surface protein CD274 (also termed PD-
L1 for programmed death ligand 1). The co-inhibitory
molecules PD-L1 (CD274) and PD-L2 (CD273) are ligands of
PD-1 (programmed death 1; CD279). Here we determine the
functional role of PD-1/PD-L pathways in human renal
allograft rejection. Treatment of human primary tubular
epithelial cells with interferon-b and -c caused a dose-
dependent and synergistic increase of PD-L1 and PD-L2
expression. Blockade of surface PD-L1, but not PD-L2, on
interferon-treated tubular epithelial cells resulted in a
significant increase in CD4þ T-cell proliferation and cytokine
production by CD4þ and CD8þ T cells. The expression of PD-
L1, PD-L2, and PD-1 mRNA and protein was upregulated in
biopsies of patients with renal allograft rejection compared
to the respective levels found in the pre-transplant biopsies.
Induction of PD-L1 was significantly associated with acute
vascular rejection. Our study suggests that the renal
epithelial PD-1/PD-L1 pathway exerts an inhibitory effect of
on alloreactive T-cell responses. The upregulation of PD-L1
on proximal tubular epithelial cells in patients with acute
allograft rejection may reduce T-cell-mediated injury.
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Acute renal allograft rejection remains a major obstacle for
long-term allograft survival as it predisposes to chronic
allograft injury with a progressive decline of renal function.
Although the various damages to the allograft (including
acute or chronic rejection) resulting in interstitial fibrosis/
tubular atrophy (IF/TA) are not unequivocal, it is widely
accepted that the incidence and severity of acute rejection is
associated with chronic organ damage and eventually
allograft survival.1
Renal proximal tubular epithelial cells (TECs) are the
main target of infiltrating alloreactive CD4þ and CD8þ T
cells causing tubulointerstitial injury.2 The local inflamma-
tion induces major histocompatibility complex (MHC) class
I and class II expression on donor TECs, allowing recognition
of allogeneic MHC/peptide complexes by recipient T cells
(signal 1).3 An additional signal 2 required for full T-cell
activation is provided by the binding of costimulatory
molecules on antigen-presenting cells to their receptors on
T cells (for example, B7/CD28). In contrast, a number of
known co-inhibitory molecules downregulate T-cell re-
sponses. PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC,
CD273) are ligands for the programmed death 1 (PD-1)
molecule that is induced on activated T and B cells. PD-L1
and PD-L2 are expressed on hematopoietic cells and
parenchymal tissues such as heart, lung, liver, placenta, and
kidney.4,5 Binding of PD-L1 or PD-L2 to PD-1 inhibits
lymphocyte activation.4,5
The expression profile of costimulatory and co-inhibitory
molecules on TECs is limited.6 Although TECs do not
express the typical costimulatory molecules B7.1 and B7.2,7,8
they express CD40 as a costimulatory molecule. PD-L1 is the
most prominent co-inhibitory molecule on TECs. Along with
others, we previously observed that PD-L1 is strongly
expressed in rejected murine kidney transplants, and that
PD-L1 is markedly upregulated on cultured murine TECs
after treatment with inflammatory cytokines.9,10 Further-
more, high PD-L1 expression by murine TECs impairs
antigen-specific CD4þ and CD8þ T-cell responses.6,9,11
Several other studies showed that the PD-1/PD-L1 pathway
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directly attenuates allograft rejection in experimental
models of heart, skin, and pancreas transplantation.12–14
Furthermore, PD-1 had a crucial role for the induction of
CD8þ T-cell tolerance in an allogeneic mixed chimerism
model.15
The functional role of PD-1/PD-L pathways in human
kidney allograft rejection is unknown. Thus, the aim of this
study was to investigate the function of PD-L1 and PD-L2 on
human TECs in modulating alloreactive CD4þ and CD8þ
T-cell responses. Furthermore, expression of PD-L1, PD-L2,
and PD-1 was evaluated in biopsies of kidney allografts with
acute and chronic rejection.
RESULTS
PD-L1 and PD-L2 surface expression on human renal TECs on
IFN-b and IFN-c treatment in vitro
To explore the functional role of PD-L1 and PD-L2 on
human TECs, we first studied the expression pattern on
cultured TECs. TECs were stimulated with human interferon
(IFN)-b and IFN-g for 48 h. PD-L1 and PD-L2 were
constitutively expressed on TECs (Figure 1a). Treatment
with either IFN-b or IFN-g was able to further upregulate the
expression of both PD-L1 and PD-L2 in a dose-dependent
manner (Figure 1a). Furthermore, stimulation of TECs with
both IFNs revealed a synergistic effect (Figure 1b). We
performed these experiments with primary TECs (n¼ 3) and
HK-2 cells and obtained similar results (data not shown).
Stimulation with IFN-b and IFN-g also strongly upregu-
lated constitutive MHC class I expression (Figure 1c). MHC
class II molecules were not constitutively expressed on TECs
(Figure 1c), but stimulation with IFN-g led to a marked
increase. IFN-b had no effect.
PD-L1 on TECs inhibited proliferation and cytokine
production of CD4þ T cells
In these experiments, alloreactive CD4þ T-cell proliferation
was performed by incubating PHA-activated human CD4þ
T cells with IFN-pretreated human TECs. Anti-PD-L1 and
anti-PD-L2 monoclonal antibodies (mAbs) or isotype
controls were included to examine the function of renal
epithelial PD-L1 and PD-L2. As shown in Figure 2a,
compared to the anti-CD3 mAb-induced CD4þ T-cell
proliferation, TECs generated from nephrectomized kidneys
of two patients (P1 and P2 TEC) induced a very weak T-cell
proliferation. Importantly, double blockade of PD-L1 and
PD-L2 on both P1 and P2 TECs significantly increased the
CD4þ T-cell proliferation and cytokine production (Figure
2a and c). To further define whether the enhancement of
T-cell proliferation was mediated by the blockade of PD-L1,
PD-L2 or both, we performed single blockade. Interestingly,
inhibition of PD-L1 alone was able to augment CD4þ T-cell
proliferation, which was comparable to the responses
obtained with double blockade. In contrast, PD-L2 blockade
was not effective (Figure 2b).
The cytokine profile in the supernatants of CD4þ T cell/
TECs cocultures was investigated, including IL-2, IL-4, IL-10,
IFN-g, and tumor necrosis factor (TNF)-a. Similar to the
T-cell proliferation, TECs stimulated negligible IFN-g produc-
tion comparable to the baseline level of IFN-g production by
CD4þ T cells alone (Figure 2c). Inhibition of PD-L1 on
TECs significantly increased the IFN-g production up to
5- to 10-fold. Again, the same magnitude of IFN-g secretion was
seen when both PD-L1 and PD-L2 on TECs were blocked,
whereas inhibition of PD-L2 alone had no effect. TNF-a
secretion by CD4þ T cells was also observed only after PD-
L1, but not after PD-L2 blockade (data not shown). Although
proliferation of CD4þ T cells after blockade of PD-L1 on
TECs could be measured, IL-2 production was not detectable
in the supernatants of CD4þ T cell/TECs coculture after 72 h
(data not shown). In addition, CD4þ T cells did not produce
IL-4 or IL-10 after stimulation with TECs under these
experimental conditions (data not shown).
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Figure 1 | Flow cytometric analysis of PD-L1/PD-L2 and MHC
class I/class II on human primary tubular epithelial cells
(TECs). (a and b) Human primary TECs were stained with
monoclonal antibodies for PD-L1 and PD-L2 expression after 48 h
stimulation with interferon (IFN)-b or IFN-g at different doses (a)
as well as after treatment with both cytokines together (b) and
compared to untreated controls. (c) Major histocompatibility
complex (MHC) class I and class II expression was determined with
antibodies against HLA-ABC and HLA-DR, respectively. The results
are representative of the three patients’ TECs as well as the cell
line HK-2.
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PD-L1 on TECs inhibited cytokine production of CD8þ T cells
To study the alloreactive CD8þ T-cell response after
stimulation with TECs, we used TECs pretreated with IFNs
as stimulators to test the IFN-g production by PHA-activated
CD8þ T cells. Similar to the CD4þ T-cell responses, TECs
alone only induced weak CD8þ T-cell activation, measured
by a low IFN-g production in the supernatants of T cell/TECs
cocultures. Blockade of both PD-L1 and PD-L2 on the TECs
significantly increased the IFN-g production of CD8þ T cells
by two- to threefold (Figure 3). In analogy to the CD4þ
T-cell responses, single PD-L1 blocking on TECs increased the
IFN-g production of CD8þ T cells to the same magnitude as
with the double blocking, and no increase of IFN-g
production was obtained by PD-L2 blocking (Figure 3).
PD-L1 on TECs inhibited the IFN-c production of alloreactive
CD4þ and CD8þ T cells
Because PHA activates T cells nonspecifically and indepen-
dently of TCR signaling, our results may not be completely
transferable to alloreactive T-cell responses. Thus, we
repeated these experiments by using allogeneic and auto-
logous pre-stimulation of CD4þ and CD8þ T cells.
Autologously and allogeneically pre-stimulated CD4þ and
CD8þ T cells were cocultured with IFN pretreated TECs of
patient 2. Because blockade of PD-L2 on TECs did not
increase the T-cell response in the previous experiments
(Figures 2 and 3), only PD-L1 blockade was performed.
Allogeneic pre-activation of CD4þ T cells with T-cell-
depleted peripheral blood mononuclear cells (PBMCs) of
patient 2 induced high amounts of IFN-g compared to
autologous pre-activation of CD4þ T cells (Figure 4a, T cells
alone), indicating that the allogeneic pre-stimulation effec-
tively activated CD4þ T cells of the healthy donor.
Restimulation of these allogeneically or autologously pre-
activated CD4þ T cells with the TECs of this patient 2 (P2
TEC) could not further increase the IFN-g secretion.
However, inhibition of PD-L1 on P2 TEC significantly
augmented the IFN-g production by allogeneically and to a
much lesser degree also by autologously pre-activated CD4þ
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Figure 3 | Interferon-c (IFN-c) production of CD8þ T cells after
stimulation with human primary tubular epithelial cells (TECs)
pretreated with IFNs. CD8þ T cells activated with PHA were
cocultured with IFN-pretreated TECs of patient 1 (P1 TEC) (1 104
cells per well) at the responder/stimulator ratio of 30:1. Before
addition of TECs to CD8þ T cells, TECs were incubated with
aPD-L1 and/or aPD-L2 antibodies or isotype control. After 48 h of
coculture, the IFN-g production of CD8þ T cells was determined.
The results represent mean values ± s.d. of triplicate wells and
are representative of CD8þ T-cell responses of four different
responders that gave similar results. *Po0.05, when compared
with isotype control (unpaired Student’s t-test).
CD4+ T cells/TEC
CD4+ T cells/TEC
O
D 
49
0 
nm
O
D 
49
0 
nm
0.45
0.35
0.25
0.15
0.05
0.45
0.35
0.25
0.15
0.05
P1 TEC + isotype
P1 TEC + αPD-L1 + αPD-L2
P2 TEC + isotype
P2 TEC + αPD-L1 + αPD-L2
T cells only + αCD3
P1 TEC + isotype
P1 TEC + αPD-L1
P1 TEC + αPD-L2
P1 TEC + αPD-L1 + αPD-L2
0 5 10 15 20 25
IF
N
-γ
 
(pg
/m
l)
CD4+ T cell:
P1 TEC:
+ + + +
+ + + +
+ + +
++ +
+
+
+
+
++
+
+
+
−
−−
− − − −
− −
−
−
−
−
−
−
− − − −
− − −
− − −
−
−
−
−
−−P2 TEC:
αPD-L1:
αPD-L2:
Isotype:
3000
2500
2000
1500
1000
500
0
0 5 10 15 20 25
***
***
***
**
**
**
***
*
***
***
***
***
***
*** **
**
**
***
**
Figure 2 |Proliferation and interferon-c (IFN-c) production of
CD4þ T cells after stimulation with human primary tubular
epithelial cells (TECs) pretreated with IFNs. CD4þ T cells
activated with PHA were cocultured with IFN-pretreated TECs of
patient 1 (P1 TEC) or of patient 2 (P2 TEC) (2 104 cells per well) at
the indicated responder/stimulator ratios of 20, 10, 5, and 2.5:1.
Before addition of TECs to T cells, TECs were incubated for 1 h
with aPD-L1 and/or aPD-L2 antibodies or isotype control. After
72 h of coculture, the proliferation (a and b) and the IFN-g
production (c) of CD4þ T cells were determined. The results
represent mean values ± s.d. of triplicate wells and are
representative of CD4þ T-cell responses of four different donors
that gave similar results. *Po0.05, **Po0.001, ***Po0.0001 when
compared with isotype control (unpaired Student’s t-test).
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T cells. As expected, the cytokine response of the allogenei-
cally pre-activated CD4þ T cells was significantly higher.
The alloreactive CD8þ T-cell response showed a similar
pattern (Figure 4c). Pre-activation of CD8þ T cells by
allogeneic CD4CD8 PBMCs of patient 2 induced moder-
ate IFN-g production. Inhibition of PD-L1 on P2 TEC
dramatically increased the IFN-g secretion of allogeneically
pre-activated CD8þ T cells. In contrast, blockade of PD-L1
on P2 TEC only slightly enhanced the IFN-g production of
autologously pre-activated CD8þ T cells. In conclusion,
these data reveal that CD4þ and CD8þ T cells pre-activated
with the patient’s allogeneic CD4CD8 PBMCs showed a
much stronger cytokine response to P2 TECs than auto-
logously pre-activated T cells.
It is known that PD-1 and PD-L1 are also expressed on
activated CD4þ and CD8þ T cells. To rule out the possibility
that blockade of PD-L1 on alloreactive T cells alone would
increase IFN-g production of those T cells, we added anti-
PD-L1 Abs to the alloreactive pre-stimulated CD4þ and
CD8þ T cells, and measured the IFN-g production in the
supernatants. Although the inhibition of PD-L1 on allo-
reactive CD4þ T cells alone slightly increased the IFN-g
secretion, this was negligible compared to the results
obtained from the stimulation of the same CD4þ T cells
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Figure 4 | Interferon-c (IFN-c) production of alloreactive CD4þ and CD8þ T cells after stimulation with human primary tubular
epithelial cells (TECs) pretreated with IFNs. CD4þ and CD8þ T cells were pre-activated with allogeneic or autologous T-cell-depleted
peripheral blood mononuclear cells (PBMCs) and were cocultured with IFN-pretreated TECs of patient 2 (P2 TEC) at a responder/stimulator
ratio of 20 and 30 for the CD4þ T cells and the CD8þ T cells, respectively (a and c). Before addition of TECs to T cells, TECs were incubated
for 1 h with aPD-L1 antibodies or isotype control. After 72 h (a) or 48 h (c) of coculture, the IFN-g production of CD4þ T cells (a) and CD8þ
T cells (c) was determined. As control, aPD-L1 or aPD-1 antibodies were also added to the alloreactive CD4þ and CD8þ T-cell cultures in the
absence of renal TECs, respectively, for determining IFN-g production in the supernatants (b and d). *Po0.05, **Po0.001, ***Po0.0001
when compared with isotype control (unpaired Student’s t-test).
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together with TECs in the presence of anti-PD-L1 blocking
Abs (Figure 4b). Similarly, blockade of PD-L1 on CD8þ
T cells alone did not increase the IFN-g production in the
supernatants (Figure 4d). In addition, blockade of the
receptor PD-1 on both alloreactive CD4þ and CD8þ
T cells with mAbs did not increase the IFN-g production
(Figure 4b and d). Thus, our results suggest that PD-L1 on
TECs has a predominant role in inhibiting alloreactive CD4þ
and CD8þ T-cell responses induced by TECs.
Strong induction of PD-L1, PD-L2, and PD-1 mRNAs in human
biopsies of kidney allograft rejection
The mRNA expression of PD-L1, PD-L2, and their receptor
PD-1 was then investigated in renal biopsies of patients with
acute kidney transplant rejection (ATR), IF/TA,16 and BK
virus nephropathy (BKN) by real-time RT-PCR. Compared
to control tissues (pretransplant biopsies; living donor n¼ 9,
deceased donor n¼ 1), PD-L1 mRNA transcript levels were
significantly increased only in renal biopsies of patients with
ATR, but not in biopsy samples from patients with IF/TA or
BKN (Figure 5a). PD-L2 mRNAwas significantly enhanced in
biopsies of patients with ATR or IF/TA (Figure 5b). In
addition, biopsies of all patients showing a high PD-L1
mRNA induction had also increased mRNA levels of PD-L2
(Pearson’s correlation, r¼ 0.6480, P¼ 0.0006). PD-1 mRNA
was also significantly induced in biopsies of patients with
ATR, IF/TA, and BKN (Figure 5c).
Patient characteristics and correlation to the PD-L1, PD-L2,
and PD-1 mRNA levels
The relevant clinical parameters including recipient age,
gender, creatinine, and proteinuria as well as histological
parameters such as scores for tubulitis, interstitial infiltration,
chronic lesions, and Banff classification at the time of biopsy
were extracted from the European Renal cDNA Bank/
Kroener-Fresenius Biopsy Bank (ERCB-KFB) (Table 1). PD-
L1, PD-L2, and PD-1 mRNA revealed no correlation to
creatinine and proteinuria levels. Possibly the cohort size was
too small for such analysis. Because follow-up data are not
routinely collected from allograft recipients in the ERCB-
KFB, a correlation with the response to treatment could not
be assessed. However, the expression of PD-L1 was
significantly increased in patients with vascular rejection
(Banff IIA and IIB) compared to tubulointerstitial rejection
(Banff IA and IB) (Figure 6a). This was not the case for PD-
L2 (data not shown). In contrast, the score for tubulitis
showed a tendency to be lower in patients with vascular
rejection (Banff IIA and IIB, Figure 6b).
PD-L1 and PD-1 localization in human allograft rejection
We speculated that the increased mRNA expression of PD-1
detected in the biopsies might be due to infiltrating
lymphocytes and the enhanced PD-L1 mRNA expression
would be expected on TECs as well as on infiltrating
leukocytes. To localize PD-L1 and PD-1, we performed
immunohistochemistry on a series of archival allograft
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Figure 5 |PD-L1, PD-L2, and PD-1 mRNA expression in human
renal biopsies. (a) Renal biopsies from patients with acute
transplant rejection (ATR, n¼ 12), interstitial fibrosis and tubular
atrophy (IF/TA n¼ 11), and BK virus nephropathy (BKN, n¼ 7) were
compared to pre-transplant tissue samples (control, n¼ 10) for the
mRNA expression of PD-L1. (b) For PD-L2, 9 samples of ATR, 8 of
IF/TA, 7 of BKN, and 10 of controls and (c) for PD-1, 8 samples of
ATR, 8 of IF/TA, 7 of BKN, and 8 of controls were analyzed. mRNA
expression of PD-L1, PD-L2, and PD-1 were normalized to the
expression of 18S rRNA and the fold inductions of the target genes
in the above-mentioned entities were calculated compared to the
control tissue (¼ 1). PD-1 mRNA expression was not detectable in
some samples that are shown below the x axis. *Po0.05,
**Po0.001, ***Po0.0001 when compared with controls
(Mann–Whitney U-test and Bonferroni correction).
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biopsies and on two renal allograft nephrectomies with severe
acute vascular rejection in addition to signs of chronic injury
(IF/TA, n¼ 2). The allograft biopsies included acute inter-
stitial rejection (Banff IB) and biopsies without acute
rejection with well-preserved tissue architecture (n¼ 3). In
allograft nephrectomies, surface expression of PD-L1 was
found on infiltrating cells in the tubulointerstitium that
displayed dendritic cell morphology (Figure 7a) and on TECs
(Figure 7a and c). Preincubation of the anti-PD-L1 antibody
with its peptide completely abolished the positive PD-L1
staining (Figure 7b). PD-1 was expressed by interstitial
infiltrating lymphocytes but not on tubular cells (Figure 7d).
DISCUSSION
The wide distribution of PD-L1 and PD-L2 in lymphoid and
parenchymal tissues4,5suggests a broad regulatory function
on various immune responses, including autoimmunity and
self-tolerance.14 Recent studies indicated an important role
Table 1 | Clinical and histological characteristics of biopsies from patients with acute transplant rejection, interstitial fibrosis/
tubular atrophy, BK virus nephropathy, and control subjects analyzed by real-time RT-PCR
Grade of damage
Biopsy group Age (year) Gender Graft Creatinine (lmol/l) Proteinuria (g per day) ci/ct int inf tub inf Banff
Acute transplant rejection
ATR1 47 M dcd 424 NA 2 3 2–3 IIB
ATR2 71 F dcd 455 0.5 2 1–2 0 IIA
ATR3 47 M dcd 240 0.1 0 2 2 IIA
ATR4 49 M dcd 720 NA 0 2 1 IIA
ATR5 61 F dcd 456 NA 0 2 3 IB
ATR6 54 F dcd 909 NA 0 2 2 IA
ATR7 49 M dcd 177 0.18 2 NA NA IA
ATR8 47 M dcd 440 0.3 0–1 2 3 IB
ATR9 65 M dcd 488 NA 2 2 2 IIA
ATR10 61 F dcd 637 NA 1 2 1 IIB
ATR11 43 M dcd 908 NA 0 2 1 IIB
ATR12 49 M NA 203 NA 0 1 2 IIA
Interstitial fibrosis/tubular atrophy
IF/TA1 46 M dcd 174 NA 1 0–1 0
IF/TA2 60 F NA 220 0.325 1 0–1 0
IF/TA3 23 F liv 188 NA 1 0–1 0
IF/TA4 66 F dcd 120 2 1–2 0 0 a
IF/TA5 32 F dcd 234 NA 3 1 0
IF/TA6 52 NA NA 548 1.82 2 0–1 0 a
IF/TA7 37 M NA 884 7 2 0 0
IF/TA8 32 M dcd 171 1.5 1–2 0–1 0 a
IF/TA9 34 F dcd 495 0.8 3 0–1 0
IF/TA10 67 M dcd 294 0.2 1 0–1 0
IF/TA11 66 M dcd 225 5 1 0–1 0
BK virus nephropathy
BKN1 37 M dcd 301 NA 0–1 2 0
BKN2 41 M dcd 539 0.4 2 1–2 3
BKN3 52 F dcd 273 8.3 0 2 2
BKN4 35 F dcd 528 1.26 2 1 0 a
BKN5 57 M dcd 426 NA 1 2 2
BKN6 66 F dcd 320 0 3 1–2 0
BKN7 40 F dcd 280 2.3 2 1–2 0–1
Control subjects
C1 35 F liv o97 o0.2
C2 39 M liv o97 o0.2
C3 55 F liv o97 o0.2
C4 41 M liv o97 o0.2
C5 61 M liv o97 o0.2
C6 58 F liv o97 o0.2
C7 27 M liv o97 o0.2
C8 NA NA dcd o97 o0.2
C9 54 F liv o97 o0.2
C10 61 F liv o97 o0.2
Banff IA/B: tubulointerstitial rejection; Banff IIA/B: vascular rejection; ci/ct: chronic interstitial fibrosis and chronic tubular atrophy; dcd: deceased donor; int inf: interstitial
infiltration/inflammation; tub inf: tubular infiltration/tubulitis; grade of damage/score 0: none or minimal, o5% for ci/ct and o10% for int inf; 1: mild (o25%); 2: moderate
o50%; 3: severe450%; for tub inf 0: no cells/tubular cross section; 1: 1–4 cells per tubular cross section; 2: 5–10 cells per tubular cross section; 3:410 cells per tubular cross
section; liv: living donor; NA: not available.
aTransplant glomerulopathy.
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for the PD-1/PD-L pathway for allograft rejection and
tolerance in experimental models.12,17 Here, we showed that
the co-inhibitory molecule PD-L1 expressed on human renal
TECs suppresses human alloreactive T-cell responses and is
associated with acute kidney allograft rejection.
Earlier studies showed that CD4þ T cells do not respond
to allogeneic TECs pretreated with IFN-g. This was in part
due to the lack of costimulation, especially the absence of
B7.1 molecules on TECs.7,18 However, our study now reveals
that the existence of the PD-1/PD-L1 co-inhibitory pathway
has a crucial role for the unresponsiveness of alloreactive T
cells toward renal TECs, because inhibition of PD-L1 on
TECs strongly augmented the CD4þ and CD8þ T-cell
responses. An increased alloreactive CD8þ T-cell response
could only be measured in terms of IFN-g production,
whereas the same CD8þ T cells were not able to lyse
allogeneic renal TECs even though they showed a strong
cytotoxic T-lymphocyte (CTL) activity to Jurkat cells (data
not shown). These results indicate that human TECs are
highly resistant to the attack of alloreactive CTLs in vitro. The
limited costimulatory molecule expression on TECs, includ-
ing the lack of strong B7/CD28 costimulation, could at least
partially explain this phenomenon.
Our results showed that IFN-b and IFN-g have a critical
role in the upregulation of the PD-L1 and PD-L2 expression
on TECs in vitro. Obata et al.19 showed that the expression of
IFN-g mRNA was strongly increased in acute and chronic
human renal allograft biopsies. It is therefore possible that,
during local inflammation, IFN-b production as part of the
innate immune response and IFN-g secretion from infiltrat-
ing alloreactive T cells are both responsible for the in vivo
increase of PD-L1 (and PD-L2) expression on renal
tubulointerstitial tissues as observed in our study. This is
consistent with the observation that the expression of PD-1 is
absent in healthy kidneys without inflammation.20 The
expression of PD-1 in allograft biopsies with acute rejection
indicates the presence of activated T cells within the inflamed
kidneys. Importantly, more intense tubulitis seems to be
associated with lower PD-L1 expression during tubulointer-
stitial rejection, whereas the opposite was observed for
vascular rejections. This may suggest that during more severe
acute vascular rejections the tubulointerstitium is partially
protected by the expression of PD-L1, whereas this is not
the case for the vascular endothelium that does not express
PD-L1 (Figure 7a). These results complement previous
observations of high PD-L1 expression on renal tubules in
other immune-mediated human renal diseases, including
diffuse proliferative lupus nephritis, IgA nephropathy,
and tubulointerstitial nephritis.10,20 Therefore there is
increasing evidence that the PD-1/PD-L1 pathway is involved
in immune-mediated human renal diseases and especially
in ATR.
It has been reported that PD-1 blockade reverses the
suppression of cancer-specific CTLs by CD4þCD25hi Tregs.21
Stroopinsky et al.22 have shown that CD4þCD25hiFoxP3þ T
cells (Tregs) were induced by allogeneic stimulation of
PBMC. This allogeneic stimulation induced human
FoxP3þ IFN-gþ T cells that markedly inhibit alloreactive
T-cell expansion. Considering the fact that Tregs express high
PD-1, one hypothesis is that the blockade of PD-L1 on TECs
in our experiments may not only inhibit the PD-1/PD-L1
pathway between alloreactive effector T cells and TECs, but
also abolish the PD-1/PD-L1 interaction between Tregs and
TECs. This might lead to the impairment of Treg function,
hence increasing the effector T-cell responses and resulting in
a higher IFN-g secretion. Further studies on the functional
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Figure 6 |PD-L1 mRNA induction is pronounced in vascular
allograft rejection. (a) Relation of PD-L1 induction between
patients suffering from acute tubulointerstitial rejection (Banff IA/
IB) and vascular rejection (Banff IIA/IIB). (b) Comparison of the
tubulitis score between tubulointerstitial rejection (Banff IA/IB)
and vascular rejection (Banff IIA/IIB) (Mann–Whitney U-test).
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PD-1
Figure 7 | Immunohistochemistry of PD-L1 and PD-1
expression on allograft biopsies. (a) In allograft nephrectomies
PD-L1 was expressed by large cells with a dendritic cell
morphology in the tubulointerstitium (arrowheads) as well as by
some tubular epithelial cells (arrows). (b) Preincubation of the
anti-PD-L1 antibody with the peptide used for immunization
completely abolished the positive staining showing specificity of
the staining. (c) Prominent expression of PD-L1 by tubular
epithelial cells (arrows). (d) PD-1-positive cells resemble small
lymphocytes (some are indicated by arrowheads), which were
present in foci of smaller and larger accumulations of infiltrating
cells (original magnifications:  100 a and b;  200 c and d).
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role of the PD-1/PD-L1 pathway between Tregs and
renal TECs would be required to clarify this point. However,
in our experiments using isolated CD8þ T cells,
CD4þCD25hiFoxP3þ Tregs were removed by the isolation
procedure, therefore making a direct effect on effector cells
much more likely.
Although PD-L2 upregulation was observed in our biopsy
samples and on IFN-stimulated TECs, it does not seem to
have an inhibitory role in human kidney transplantation.
There was no correlation to histological parameters and
in vitro blockade of PD-L2 on TECs was not effective. This
was not due to the failure of the anti-human PD-L2 mAb
included in this study because the same clone of mAb was
successfully used to inhibit PD-L2 activity of T-cell
stimulator cells by others.23 Several studies suggested distinct
roles of PD-L1 and PD-L2 in regulating T-cell activity.
Tanaka et al.24 indicated that blockade of PD-L1, but not of
PD-L2, accelerated cardiac allograft rejection associated with
an increased frequency of IFN-g-producing alloreactive T
cells and the expansion of effector CD8þ T cells. Consistent
with this observation, Sandner et al.13 showed that inhibition
of PD-L1, but not of PD-L2, enhanced CD4þ T-cell
activation in a skin graft model. The function of PD-L2
may also depend on the location of immune responses.
Habicht et al.25 showed that in the host lymphoid organs
as opposed to parenchymal tissue the in vivo activation
of both alloreactive CD4þ and CD8þ T cells was primarily
mediated by PD-L2. Furthermore, the increased prolifera-
tion of CD8þ T cells after in vivo blockade of PD-L2
was dependent on CD28-mediated costimulation signal,25
which does not have a role for TECs that do not express
B7 molecules.
Experimental models of heart12,17 and corneal allo-
grafts26–29 showed a critical and protective role of the PD-
1/PD-L1 pathway in transplantation. Although the increase
of PD-L1 on donor TECs is not sufficient to completely
prevent acute allograft rejection, our results suggest a
protective mechanism of parenchymal tissues to mitigate
alloreactive human T-cell responses and tissue injury through
PD-1/PD-L1 co-inhibitory pathway. Strategies to selectively
enhance PD-L1 expression on TECs as well as on professional
antigen-presenting cells might be therapeutically useful to
prevent ATR.
MATERIALS AND METHODS
General reagents
Cell culture reagents were obtained from Invitrogen (Gaithersburg,
MD, USA) and Sigma (St Louis, MO, USA). Human cytokines were
purchased from R&D Systems (Oxford, UK).
Human cell lines and primary TEC cultures
The human renal TEC line HK-2 was cultured in K1 medium.30
Primary cultures of human TECs were generated from healthy parts
of tumor nephrectomies. Briefly, small fragments of cortical tissue
were digested twice with type II collagenase (1mg/ml in HBSS)
(Invitrogen) for 90min at 37 1C. The cell suspension was passed
through 40 mm sieves, washed, and seeded on collagen-coated cell
culture plates in K1 medium containing human epidermal growth
factor (5 ng/ml). Next day, after washing with HBSS, fresh K1
medium was added to allow primary TECs growing at 37 1C in 5%
CO2 until confluence (5–7 days). Epithelial cell origin confirmed by
positive cytokeratin staining was more than 95%. In functional
assays, the second passage of TECs with positive cytokeratin
expression was used as antigen-presenting cells, which showed a
similar pattern of surface molecule expression and antigen-
presentation capacity compared to the original primary TECs.
Flow cytometric analysis
Human TECs were harvested by trypsinization, washed, and stained
with mAbs (all mouse anti-human) against PD-L1 (clone MIH1),
PD-L2 (clone MIH18), HLA-ABC (clone W6/32), and HLA-DR
(clone LN3). mAbs were purchased from eBioscience (San Diego,
CA, USA). Cells were analyzed using a FACSCantoII flow cytometer
(BD Biosciences, San Jose, CA, USA) and FlowJo software Version 7
(TreeStar, Ashland, OR, USA).
Isolation and activation of human CD4þ and CD8þ T cells
in vitro
Human PBMCs were isolated from heparinized whole blood of
healthy volunteers (n¼ 5) and of patient 2 (who provided the tissue
for isolating TECs) using Lymphoprep (Axis-Shield PoC AS, Oslo,
Norway) according to the manufacturer’s protocol. PBMCs were
washed with phosphate-buffered saline three times followed by
CD4þ and CD8þ T-cell isolation with human CD8 and CD4
MACS microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany),
respectively. CD4þ and CD8þ T cells were then pre-activated either
with PHA or allogeneic PBMCs to upregulate PD-1 expression on T-
cell surfaces.
PHA activation. Isolated CD4þ and CD8þ T cells of healthy
donors were adjusted to 2 106 cells per ml in Iscove’s modified
Dulbecco’s medium supplemented with 10% fetal bovine serum,
seeded into 24-well plates and incubated at 37 1C, 5% CO2.
Activation of T cells was performed by adding 2 mg/ml of PHA for 5
days.
Allogeneic and autologous activation. The T-cell-depleted
fraction of PBMCs (CD4CD8 PBMCs) of patient 2 was irradiated
with 30Gy and then cocultured with purified CD4þ or CD8þ T
cells of one fully HLA-mismatched healthy donor (see below) at a
ratio of 2:1 (T cells/PBMCs) for 3 days in the presence of human IL-
2 (5 ng/ml). As a control, CD4þ and CD8þ T cells of the same
healthy donor were also stimulated with their own CD4CD8
PBMCs (autologous stimulation) under the same conditions. Low-
resolution HLA typing of A, B, DR, and DQ loci using PCR-SSP
method (PCR with sequence-specific primers) of the responders and
patients presented in Figures 2–4 was performed and is indicated
below:
K Responder 1: A*02, A*24, B*51, B*57, DRB1*01, DRB1*07,
DQB1*05, DQB1*0303
K Responder 2: A*11, A*23, B*44, B*40, DRB1*07, DRB1*09,
DRB4*, DQB1*02, DQB1*0303
K Patient 1: A*02, A*02, B*35, B*50, DRB1*07, DRB1*07, DRB4*,
DQB1*02, DQB1*02
K Patient 2: A*01, A*26, B*07, B*35, DRB1*11, DRB1*15, DRB3*,
DRB5*, DQB1*0301, DQB1*06
For all responder-stimulator combinations tested, we found HLA
mismatches in MHC class I and class II loci.
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Alloreactive CD4þ T-cell proliferation induced by TECs
Human primary TECs were pretreated with human IFN-b and
IFN-g (100U/ml each) for 2 days. Cells were then harvested by
trypsinization, washed, and irradiated with 60Gy. Irradiation did
not influence the expression of PD-L1 and PD-L2 (data not shown).
After washing, we resuspended TECs in Iscove’s modified Dulbecco’s
medium and seeded them in 96-well plates. TECs were preincubated
with the relevant mAbs (PD-L1, PD-L2, or isotype control) for 1 h at
37 1C before addition of pre-activated CD4þ T cells at the indicated
T cell/TEC ratios. T-cell proliferation was determined after 72 h of
co-incubation by using the nonradioactive colorimetric CellTiter 96
AQueous One Solution Cell Proliferation Assay kit (Promega,
Madison, WI, USA) according to the manufacturer’s protocol.
Results were presented as the value of the OD at 490 nm after
subtraction of the OD values from medium alone and calculated as
follows: ODexperimentalODTEC aloneODT cell alone.
Alloreactive CD8þ T-cell cytokine production stimulated by
TECs
Human primary TECs were pretreated with IFN-b and IFN-g for
2 days, harvested, and preincubated with the relevant mAbs or isotype
control for 1 h, and then seeded in 96-well plates. Pre-activated
human CD8þ T cells were added at a responder/stimulator ratio of
30:1 (3 105 CD8þ T cells/1 104 TECs) for 48h.
Measurement of cytokines
Cytokine production was determined in the coculture supernatants
after 48 h (CD8þ T-cell response) and 72 h (CD4þ T-cell response),
respectively, either by human-specific enzyme-linked immunosor-
bent assay kits for IFN-g or IL-2 (eBioscience) or by the BD CBA
Flex Sets (BD Biosciences) according to the manufacturer’s protocols.
Quantitative real-time PCR of renal biopsies
Human renal biopsy specimens were procured in an international
multicenter study, the ERCB-KFB. Biopsies were obtained from
patients after informed consent and with approval of the local ethics
committees. Clinical characteristics of all patients are shown in
Table 1. Tubulointerstitial tissue was prepared and analyzed by real-
time RT-PCR as reported earlier.31 Predeveloped TaqMan reagents
were used for human PD-L1 (CD274) (NM_014143.2), PD-L2
(CD273, PDCD1LG2) (NM_025239.2), and PD-1 (PDCD1, CD279)
(NM_005018.1) as well as the housekeeper genes (GAPDH and
18SrRNA; Applied Biosystems, Foster City, CA, USA). The mRNA
expression was analyzed by standard curve quantification. Normal-
ization to both housekeeper genes gave comparable results; data
based on 18S rRNA are shown.
Immunohistochemistry
Immunohistochemistry was performed as previously described.32
The biopsies were archival materials collected retrospectively at the
University of Vienna (2006–2008). In brief, sections were dewaxed in
xylene, rehydrated in a series of graded ethanols, and incubated in
3% hydrogen peroxide (to block endogenous peroxidases). To block
endogenous biotin, we used the Avidin/Biotin blocking Kit (Vector,
Burlingame, CA, USA). Antigen retrieval was performed in an
autoclave oven in antigen retrieval solution. Incubation with the
primary antibody was performed for 1 h or overnight. Incubation
with biotinylated secondary antibodies was for 30min, followed by
the ABC reagent. For PD-1, we used two consecutive secondary
antibodies to enhance the signal. 3,30-Diaminobenzidine (Sigma,
Taufkirchen, Germany) with metal enhancement (resulting in a
black colored product) served as detection system. The rabbit
polyclonal antibody against PD-L1 (ab41890; Abcam, Cambridge,
UK) was used in a dilution of 0.5 mg/ml (1:400 in 10% nonfat dry
milk). The antibody was raised against a peptide corresponding to
amino acids 144–291 of human PD-L1. The peptide was used to
block the signal by preincubation of the antibody as additional
control. Furthermore, nonimmune rabbit serum was used as a
negative control. The monoclonal mouse anti-human PD-1 anti-
body (clone MIH4; NatuTec, Frankfurt am Main, Germany) was
used in a dilution of 40 mg/ml. Isotype matched mouse IgG1 was
used as negative control.
Statistics
All in vitro cell experiments were performed in triplicates and
were repeated at least twice. Data are expressed as mean ± s.d.
The unpaired Student’s t-test was used to analyze all data of
the in vitro experiments. Mann–Whitney test was used to perform
statistical analysis of PD-L1, PD-L2, and PD-1 mRNA expression in
human biopsies. Additional Bonferroni correction was applied to
assess for multiple testing for the mRNA levels. Pearson’s correlation
was conducted to correlate mRNA expressions to the clinical
characteristics. Significance was accepted at Pp0.05.
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